MO70-2 Pegfilgrastim with Second-Line Amrubicin for Relapsed Small Cell Lung Cancer: Single Institution Experience

Amrubicin (AMR) is an active agent for relapsed small-cell lung cancer (SCLC), but its efficacy is compromised by severe neutropenia. The rates of febrile neutropenia (FN) induced by AMR were reported to be 5-27% in clinical trials, as well as 36% by retrospective data in our institution. After the approval of pegfilgrastim (PEGF) for primary prophylaxis of FN in our country, we have used PEGF mandatorily in AMR treatment.